This is the authors' abstract. We don't add key points for this paper.
Analysis of the brain specific biomarkers amyloid beta(42) (Abeta(42)) and total tau (t-tau) protein in cerebrospinal fluid (CSF) has a sensitivity and specificity of more than 85% for differentiating Alzheimer's Disease (AD) from non-demented controls. International guidelines are contradictory in their advice on the use of CSF biomarkers in AD diagnostics, resulting in a lack of consistency in clinical practice. We present three case reports that illustrate clinical practice according to the Dutch and European guidelines and portray the value of CSF biomarker analysis as an add-on diagnostic to the standard diagnostic workup for AD.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Slats et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: